PDGFR-α as response marker for PM00104 treatment

[FR] La présente invention concerne l'utilisation de PM00104 dans le traitement du cancer chez des patients ayant des tumeurs ayant un certain profil de marqueurs moléculaires, en particulier, ayant de faibles taux d'expression de PDGFR-α. L'invention concerne en outre des procédés pour produire une chimiothérapie personnalisée avec PM00104 de patients cancéreux basée sur lesdits marqueurs moléculaires de tumeur.

[EN] The present invention relates to use of PM00104 in the treatment of cancer in patients having tumors with certain molecular markers profile, in particular, having low PDGFR-α expression levels. The invention also relates to methods for providing personalized PM00104 chemotherapy to cancer patients based on said tumor molecular markers.

70 páginas, 12 figuras, 5 tablas. Fecha de solicitud internacional: 22/10/2010; Fecha de prioridad 22/10/2009. IPC: C12Q 1/68; A61K 31/015. Solicitantes: Pharma Mar, S. A.

Peer reviewed

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average